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Abstract
Background: In order to define adequate radiation portals in nodal positive prostate cancer a detailed knowledge
of the anatomic lymph-node distribution is mandatory. We therefore systematically analyzed the localization of
Choline PET/CT positive lymph nodes and compared it to the RTOG recommendation of pelvic CTV, as well as to
previous work, the SPECT sentinel lymph node atlas.
Methods: Thirty-two patients being mostly high risk patients with a PSA of 12.5 ng/ml (median) received PET/CT
before any treatment. Eighty-seven patients received PET/CT for staging due to biochemical failure with a median
PSA of 3.12 ng/ml. Each single PET-positive lymph node was manually contoured in a “virtual” patient dataset to
achieve a 3-D visualization, resulting in an atlas of the cumulative PET positive lymph node distribution. Further the
PET-positive lymph node location in each patient was assessed with regard to the existence of a potential geographic
miss (i.e. PET-positive lymph nodes that would not have been treated adequately by the RTOG consensus on CTV
definition of pelvic lymph nodes).
Results: Seventy-eight and 209 PET positive lymph nodes were detected in patients with no prior treatment and in
postoperative patients, respectively. The most common sites of PET positive lymph nodes in patients with no prior
treatment were external iliac (32.1 %), followed by common iliac (23.1 %) and para-aortic (19.2 %). In postoperative
patients the most common sites of PET positive lymph nodes were common iliac (24.9 %), followed by external iliac
(23.0 %) and para-aortic (20.1 %). In patients with no prior treatment there were 34 (43.6 %) and in postoperative patients
there were 77 (36.8 %) of all detected lymph nodes that would not have been treated adequately using the RTOG CTV.
We compared the distribution of lymph nodes gained by Choline PET/CT to the preexisting SPECT sentinel lymph node
atlas and saw an overall good congruence.
Conclusions: Choline PET/CT and SPECT sentinel lymph node atlas are comparable to each other. More than one-third
of the PET positive lymph nodes in patients with no prior treatment and in postoperative patients would not have been
treated adequately using the RTOG CTV. To reduce geographical miss, image based definition of an individual target
volume is necessary.
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Background
Treatment strategies for high risk or nodal positive pros-
tate cancer (PCA) remain ill defined. Different scenarios
may be distinguished: Treatment of lymphatic pathways
during radiotherapy in high risk, pN+ or cN+ PCA pa-
tients or treatment of isolated secondary lymphatic re-
lapses. In order to define adequate radiation portals for
any of the given scenarios a detailed knowledge of the
lymph-node distribution is mandatory. In previous work,
single photon emission computed tomography (SPECT)
sentinel lymph node data were used to develop a realis-
tic anatomic atlas [1–3]. However a shortcoming of any
sentinel lymph node based atlas is the fact that only the
putative drainage pathways are analyzed. The real distri-
bution of pathologically affected lymph nodes is still not
visualized. Until the introduction of PET-based imaging,
the quality (sensitivity and specificity) of lymph-node diag-
nostics in PCA had been limited. Choline PET/CT offers
a sensitivity and specificity of 84 % (95 % CI, 68–93 %)
and 79 % (95 % CI, 53–93 %) in staging patients with yet
untreated prostate cancer [4]. In restaging patients with
biochemical failure Choline PET/CT has an even higher
sensitivity and specificity of 85 % (95 % CI, 79–89 %) and
88 % (95 % CI, 73–95 %) [4]. In order to overcome the
inherent limitation of the sentinel lymph node atlas men-
tioned above, we analyzed the anatomical distribution of
Choline PET/CT positive lymph nodes in untreated pa-
tients and patients after radical prostatectomy. We com-
pared this anatomic atlas to the RTOG recommendation
of pelvic CTV [5] as well as to the SPECT sentinel lymph
node atlas.
Methods
Data acquisition and patients’ characteristics
Patients were selected from a single-center database of
1191 F-18-Fluoroetyhlcholine (18F-FEC) or C-11-Choline
PET scans performed from 2004 to 2012 at the Department
of Nuclear Medicine, Ludwig-Maximilians-University Hos-
pital Munich. One hundred and twenty-eighth patients
were identified with PET positive lymph nodes and were
available for follow-up. Patients who had simultaneously a
hematogenous spread of cancer or PET positive lymph
nodes above the diaphragm were excluded. One hundred
and twelve of the 128 identified patients had a F-18-
Fluoroetyhlcholine and 16 patients had a C-11-Choline
PET/CT, as over time the tracer used had been changed
from C-11-Choline to F-18-Fluoroethylcholine. Thirty-two
patients received PET/CT before any surgical or radiother-
apy treatment, hence with completely intact lymphatic
pathways. Most of these patients (n = 26) (Table 1) were
high risk patients according to the risk group definition of
D’Amico [6] and in five of these patients androgen
deprivation therapy had been started before PET/CT had
been performed. PSA at the time of PET/CT in this group
was 12.5 ng/ml (median). Ninety-six patients received
PET/CT for staging due to PSA relapse after primary
treatment: 87 patients postoperatively, 8 patients after
definitive radiotherapy and 1 patient after high-intensity
Table 1 Patients’characteristics – patients with no prior
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focused ultrasound (HIFU). All patients with radical
prostatectomy as primary treatment received lymphad-
enectomy at the time of radical prostatectomy: In mean
12.8 lymph nodes were removed and 1.5 of these lymph
nodes (mean) were pathologically proven as metastases.
As the lymphatic pathways of patients with definitive
radiotherapy and HIFU were not surgically changed be-
fore receiving a PET/CT, these patients were excluded
from generating an anatomic atlas for patients with
PSA relapse after initial curative treatment. Postopera-
tive patients (Table 2), who received a PET/CT due to
PSA relapse, had in median a PSA of 3.12 ng/ml before
PET/CT. None of these patients had ongoing androgen
deprivation therapy at the time of PET/CT. Fifty-eight
patients of this group had a locally advanced tumor
(≥pT3a) and 30 patients had evidence of pathologic
lymph nodes (pN1) at radical prostatectomy. Thus this
PET/CT derived anatomic atlas is based on 32 patients
with no prior treatment and on 87 patients after radical
prostatectomy and lymphadenectomy.
PET/CT imaging
Whole body PET/CT images extending from the base of
the skull to the mid-thigh were acquired using a GE
Discovery PET/CT 690, a Siemens Biograph 64 True-
Point PET/CT (Siemens Medical Solutions) or a Philips
Gemini PET/CT scanner (Philips Medical Systems).
Emission scans were initiated 60 min following intraven-
ous administration of approximately 300 MBq 18F-FEC
(n = 106 patients) or 5 min after administration of ap-
proximately 500 MBq C11-Choline (n = 13 patients).
Diagnostic CT scans (100-190mAs, depending on the
scanned organ region, 120 kV) were acquired with intra-
venous injection of iodine-containing contrast agent
(Ultravist 300, Schering; or Imeron 300, Bracco; 2.5 mL/s)
at a dose adjusted for body weight. Initiation of CT acqui-
sition was delayed 50 s after injection of the contrast agent
in order to depict the portal venous phase. Lymph nodes
with pathologically increased tracer accumulation dis-
tinctly in excess of physiologic uptake were identified as
positive nodes.
Atlas of lymph node distribution
To allow a systematic topographic mapping of the lymph
node locations, the cross-sectional nodal atlas published
by Martinez-Monge et al. was used [7]. For each patient
the number and location of the affected, PET-positive
lymph nodes were documented. Beyond summarizing
these data in a table, each single PET-positive lymph
node was manually contoured in a “virtual” patient data-
set to achieve a 3-D visualization of the cumulative PET
positive lymph node distribution (Fig. 1a and b). The
Oncentra MasterPlan (Version 4.3, Elekta, Crawley, UK)
planning system was used for contouring and generating


















7 (3 + 4) 18 (20.7)

























Hegemann et al. Radiation Oncology  (2016) 11:37 Page 3 of 8
3-D images for the atlas. Moreover, the PET-positive
lymph node location in each patient was assessed with
regard to the existence of a potential geographic miss
(i.e. PET-positive lymph nodes that would not have been
treated adequately by the RTOG consensus on clinical
target volume definition of pelvic lymph nodes [5]).
Results
Location and distribution of PET positive lymph nodes
PET/CT images of each single PET positive lymph node
were available as a 3-D reconstruction with individual
coronal, axial and sagittal sections. During the system-
atic topographic evaluation of the lymph node locations,
using the cross-sectional atlas published by Martinez-
Monge [7], we observed a wide inter-individual variety
of anatomic conditions (namely, the correlation between
bone structures and vessel/bifurcation sites). To allow
for a consistent definition of a lymph node location, we
referred generally to the topographic sites of the vessel/
bifurcation sites (not to bony landmarks as given by an
axial section in computed tomography). All in all 287
PET positive lymph nodes were detected in all patients
(Fig. 1a and b; Table 3). With an incidence of ≥10 % PET
positive lymph nodes were seen in the area of external
iliac (73 lymph nodes; 25.4 %), common iliac (70 lymph
nodes; 24.4 %), para-aortic (57 lymph nodes; 19.9 %) and
internal iliac (37 lymph nodes; 13.0 %). Since it is highly
likely, that the surgical intervention has changed the
lymphatic drainage, we analyzed the distribution of PET
positive lymph nodes in postoperative patients and in
patients with no prior treatment separately. Thus 78
PET positive lymph nodes were detected in patients with
no prior treatment (Fig. 1a) and 209 PET positive lymph
nodes were seen in postoperative patients (Fig. 1b). The
detailed distribution and number of PET positive lymph
nodes is shown in Table 4 for patients with no prior
treatment and in Table 5 for postoperative patients. The
number of positive lymph nodes per region ranged from
0 to 25 in patients with no prior treatment (median
three lymph nodes) and from 0 to 52 in postoperative
patients (median seven lymph nodes). The most com-
mon sites of PET positive lymph nodes in patients with
no prior treatment were external iliac (25 lymph nodes;
32.1 %), followed by common iliac (18 lymph nodes;
23.1 %) and para-aortic (15 lymph nodes; 19.2 %). Fewer
or no PET positive lymph nodes were found internal pu-
dendal, rectal inferior/superior, at the periprostatic
lymphatic plexus, at the seminal vesicle lymphatic plexus
and sacral.
In postoperative patients the most common sites of
PET positive lymph nodes were common iliac (52 lymph
nodes; 24.9 %), followed by external iliac (48 lymph
nodes; 23.0 %) and para-aortic (42 lymph nodes; 20.1 %).
Fewer or no PET positive lymph nodes were found in
this group rectal inferior/superior, at the periprostatic
lymphatic plexus, at the seminal vesicle lymphatic plexus
and sacral. Sixty-seven of the 87 postoperative patients
(77.0 %) had a PSA at the time of Choline PET/CT
above the optimal PSA cutoff of ≥1.05 ng/ml (median
4.02 ng/ml; range 1.10–56.0) [8]. In this group a high
number of non-pelvic lymph node findings (42 PET-
positive paraaortic nodes) was seen.
PET/CT-derived atlas
In addition to summarizing the distribution of PET-
positive lymph nodes in tables, each single lymph node
and its relation to vessels, bone, rectum, bladder, pros-
tate and seminal vesicles were manually contoured in a
“virtual” patient dataset, resulting in a 3-D visualization
(Fig. 1a and b). The maximum standardized uptake value
Fig. 1 a Distribution and geographic miss according to RTOG – CTV (red) of PET positive lymph nodes in patients with no prior treatment (n = 32);
b Distribution and geographic miss according to RTOG – CTV (red) of PET positive lymph nodes in postoperative patients (n = 87)
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(SUV max) of the positive lymph node findings was in
patients with no prior treatment in median 3.9 (mean:
5.3, range: 1.8–16.9) and in postoperative patients in
median 5.1 (mean: 6.6; range 1.4–26).
Geographic miss
A target volume according to the RTOG consensus of
treatment of pelvic lymph nodes was further contoured
in the “virtual” patient dataset and all positive lymph
nodes findings were evaluated in regard to a potential
geographic miss. Figure 1a and b show the cumulative
PET-positive lymph node distribution of patients with
no prior treatment and of postoperative patients with
the RTOG CTV demonstrating a potential geographic
miss. Figure 2 shows schematically the distribution of all
PET-positive lymph nodes with the corresponding per-
centages of geographic miss. In patients with no prior
treatment (n = 32) there were 24 regions with 34 lymph
nodes involved that would not have been treated ad-
equately using the RTOG clinical target volume defin-
ition for pelvic lymphatic drainage (“geographic miss”).
In postoperative patients (n = 87) there were 55 of 161
(34.2 %) suspicious lymph node areas and 77 of all de-
tected lymph nodes (36.8 %) that would not have been
Table 4 Number and location of PET positive lymph nodes in patients with no prior treatment (n = 32)
Location Region affected Lymph nodes affected n;





Internal pudendal nodes 2 2 (2.6) 0 0
Inferior rectal nodes 0 0
Periprostatic lymphatic plexus 1 1 (1.3) 0 0
Seminal vesicle lymphatic plexus 0 0
Perirectal lymphatic plexus 3 4 (5.1) 3 4 (100)
Perivesical lymphatic plexus 3 3 (3.8) 3 3 (100)
Sacral nodes 0 0
Internal iliac nodes 7 7 (8.9) 0 0
External iliac nodes 20 25 (32.1) 4 4 (16.0)
Superior rectal nodes 0 0
Common iliac nodes 12 18 (23.1) 4 5 (27.8)
Para-aortic nodes 7 15 (19.2) 7 15 (100)
Inguinal nodes 3 3 (3.9) 3 3 (100)
Total 58 78 24 34 (43.6)
Table 3 Number and location of PET positive lymph nodes in all patients (n = 119)
Location Region affected Lymph nodes affected n;





Internal pudendal nodes 7 7 (2.4) 0 0
Inferior rectal nodes 0 0
Periprostatic lymphatic plexus 1 1 (0.3) 0 0
Seminal vesicle lymphatic plexus 0 0
Perirectal lymphatic plexus 10 11 (3.8) 8 9 (81.8)
Perivesical lymphatic plexus 10 11 (3.8) 7 7 (63.6)
Sacral nodes 3 6 (2.1) 2 5 (83.3)
Internal iliac nodes 32 37 (13.0) 0 0
External iliac nodes 60 73 (25.4) 7 7 (9.6)
Superior rectal nodes 2 2 (0.7) 2 2 (100)
Common iliac nodes 52 70 (24.4) 11 12 (17.1)
Para-aortic nodes 31 57 (19.9) 31 57 (100)
Inguinal nodes 11 12 (4.2) 11 12 (100)
Total 219 287 79 111 (38.7)
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treated sufficiently. The detailed number, sites and pro-
portions of geographic misses are shown in Tables 3, 4
and 5 and Figs. 1a, b and 2. Regarding the number of all
detected PET-positive lymph nodes, the lymph node
areas with the highest probability of geographic miss in
patients with no prior treatment were perirectal and
perivesical lymphatic plexus (100 %), para-aortic nodes
(100 %) and inguinal nodes (100 %). In postoperative
patients, superior rectal nodes (100 %), para-aortic nodes
(100 %), inguinal nodes (100 %), sacral nodes (83.3 %) and
perirectal lymphatic plexus (71.4 %) were not treated
adequately by the RTOG CTV.
Discussion
An awareness of the great variability of prostate cancer
lymph node metastases is important for anyone who treats
lymphogenous-metastasized prostate cancer. There are a
few surgical and radiotherapy driven studies on mapping
Table 5 Number and location of PET positive lymph nodes in postoperative patients (n = 87)
Location Region affected Lymph nodes affected n;





Internal pudendal nodes 5 5 (2.4) 0 0
Inferior rectal nodes 0 0
Periprostatic lymphatic plexus 0 0
Seminal vesicle lymphatic plexus 0 0
Perirectal lymphatic plexus 7 7 (3.3) 5 5 (71.4)
Perivesical lymphatic plexus 7 8 (3.8) 4 4 (50)
Sacral nodes 3 6 (2.9) 2 5 (83.3)
Internal iliac nodes 25 30 (14.4) 0 0
External iliac nodes 40 48 (23.0) 3 3 (6.3)
Superior rectal nodes 2 2 (1) 2 2 (100)
Common iliac nodes 40 52 (24.9) 7 7 (13.5)
Para-aortic nodes 24 42 (20.1) 24 42 (100)
Inguinal nodes 8 9 (4.3) 8 9 (100)
Total 161 209 55 77 (36.8)
Fig. 2 Schematic distribution of PET positive lymph nodes in all patients (n = 119) Anatomical regions and distribution (percentages in white square
frames) of all detectable PET positive lymph nodes (n = 287). Main regions of geographical misses (red), when RTOG-Consensus (Lawton et al. [5]) for
standard CTV delineation is used
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and extent of lymph node metastases in patients with
newly diagnosed prostate cancer like the study of Heiden-
reich et al. [9], Joniau et al. [10], Ganswindt et al. [3] and
Meijer et al. [11]. These studies aim to reduce the geo-
graphical miss of lymph node metastases while treating
prostate cancer patients. They either performed an ex-
tended lymphadenectomy [9], or used for the clinical tar-
get volume the information of MR lymphography [12] or
single photon emission computed tomography (SPECT)
imaging [2] instead of applying the CTV as proposed by
the RTOG consensus [5]. All of these studies were per-
formed in patients with newly diagnosed prostate cancer,
similarly to our 32 patients who received a Choline PET/
CT as a primary staging. Our anatomic atlas based on
Choline PET/CT as information for mapping prostate
cancer lymph nodes is comparable to the anatomic atlases
of Ganswindt et al. [3] and Meijer et al. [11]: the most
common suspicious lymph node areas were found simi-
larly to our study in the external, internal and common
iliac and para-aortic regions. Unlike their studies there
were fewer patients in our study who had PET-positive
lymph node findings in the sacral or perirectal area. Simi-
larly to the study of Meijer et al. who also applied the
RTOG CTV to estimate a potential miss, we observed a
geographical miss in the perirectal and perivesical lymph-
atic plexus and para-aortic nodes. To our best knowledge,
there are no detailed mapping studies on prostate lymph
node metastases using PET/CT imaging so far. Potentially
this is the first Choline PET/CT derived atlas of prostate
lymph node metastases in patients with no prior treat-
ment. All three studies on the geographical distribution of
lymph node metastases of patients with no prior treat-
ment nevertheless show the need of an adequate imaging
method before performing an individualized radiotherapy
treatment of the lymphatic pathways with minimal geo-
graphical miss.
We do not know any other Choline PET/CT based
anatomic atlas describing lymph node recurrences after
radical prostatectomy together with pelvic lymphadenec-
tomy. In Table 5 the wide variability of lymph node me-
tastases with most lymph node findings in the external,
internal and common iliac and para-aortic regions of
lymphatic drainage is demonstrated. Many of these PET-
positive lymph nodes would not be treated adequately
by only applying the RTOG CTV. Nevertheless one has
to say that this CTV has been developed for high-risk
prostate cancer patients prior to radiotherapy as primary
treatment and can therefore not be automatically applied
to postoperative patients. Further one has to state, that
67 of the 87 postoperative patients (77.0 %) had a PSA
at the time of Choline PET/CT well above the optimal
PSA cutoff of ≥1.05 ng/ml (median 4.02 ng/ml; range
1.10–56.0). Thus it is not surprising that these patients
had a high number of non-pelvic lymph node findings.
The anatomic extent of lymph node involvement depends
on well-known risk factors like Gleason score and PSA.
Taking into account these factors, a Choline PET/CT
should be performed before any irradiation in these high
risk groups. Nevertheless the sole treatment of the PET-
positive lymph nodes is not reasonable, because Choline
PET/CT, as Tilki et al. showed [13], underestimates the
true extent of affected lymph nodes. Tilki et al. performed
a lymphadenectomy in patients with rising prostate spe-
cific antigen after radical prostatectomy and compared the
histologic results with the findings of 18F-FEC PET/CT.
They concluded that a positive 18F-FEC PET/CT result
correctly predicts the presence of lymph node metastases
in the majority of prostate cancer patients with biochem-
ical failure after radical prostatectomy but does not allow
for localization of all metastatic lymph nodes and there-
fore is not adequately accurate for the precise estimation
of extent of nodal recurrence in these patients [13]. There-
fore salvage lymphadenectomy and/or salvage radiother-
apy due to rising PSA after primary curative radical
prostatectomy should not only be performed in the region
of the PET-positive lymph nodes but in the adjacent
lymph node areas, as they might often be microscopically
affected without a PET-positive signal. With prostate-
specific membrane antigen (PSMA) PET/CT one expects
to have an even better sensitivity and specificity in detect-
ing affected lymph nodes [14]. Until now large numbers of
lymph node positive prostate cancer patients diagnosed by
PSMA PET/CT are missing and it remains questionable,
whether the anatomic distribution of PET positive lymph
nodes in prostate cancer will be changed by the usage of
PSMA instead of Choline as a tracer.
Conclusions
Choline PET/CT and SPECT sentinel lymph node atlases
are comparable to each other. In both atlases describing
patients prior to any treatment the most common suspi-
cious lymph node areas were the external, internal and
common iliac and para-aortic regions. Similarly, in post-
operative patients most PET positive lymph node findings
were in the external, internal and common iliac and para-
aortic regions of lymphatic drainage. More than one-third
of the PET positive lymph nodes in patients with no prior
treatment and in postoperative patients would not have
been treated adequately using the RTOG CTV. To reduce
geographical miss, image based definition of an individual
target volume is necessary. The extent of a possible geo-
graphic miss while using the RTOG CTV can be exem-
plarily seen in the present study.
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